New York, February 2, 2026, 17:20 EST — After-hours update
- DaVita shares jumped roughly 12% in after-hours trading following the release of their quarterly earnings and 2026 profit forecast.
- The dialysis provider projected adjusted profit per share for 2026 that exceeds Wall Street expectations.
- Investors want more clarity on reimbursement rates, costs, and patient volumes during the company’s conference call.
DaVita’s shares surged 11.7% to $124.17 in after-hours trading Monday following a quarterly earnings beat and a 2026 profit outlook that outpaced analyst forecasts. The kidney dialysis provider’s stock had closed the regular session up 1.7% at $111.21.
DaVita forecast adjusted earnings of $13.60 to $15.00 per share for 2026, beating the $12.65 average analysts’ estimate, according to LSEG data. The company posted a fourth-quarter adjusted profit of $3.40 per share on $3.62 billion in revenue, both topping expectations. DaVita continues to manage the impact of a ransomware attack disclosed last year that disrupted operations and compromised data for 2.7 million people.
DaVita’s CEO Javier Rodriguez said the company “delivered once again in 2025,” despite a “challenging environment.” The firm reported free cash flow of $1.024 billion last year, after capital expenditures. For 2026, it projects free cash flow between $1.0 billion and $1.25 billion, with adjusted operating income expected to range from $2.085 billion to $2.235 billion. The company also bought back 12.7 million shares in 2025. PR Newswire
Dialysis is a stable industry, yet its margins fluctuate with changes in reimbursement and labor expenses. Investors are closely watching for evidence that the sector can control costs without outpacing payments from insurers and government programs.
DaVita pointed to higher reimbursement rates and a seasonal uptick from flu shots as drivers behind its quarterly profit and revenue gains. These elements tend to be uneven, so investors will probably push management for clarity on what’s sustainable through 2026.
DaVita’s earnings call is set for 5 p.m. ET, accessible via a webcast link on its investor relations page. As of Sept. 30, 2025, the company reported serving roughly 293,200 patients through 3,247 outpatient dialysis centers.
Still, some weak points remain. DaVita’s latest disclosure revealed that U.S. dialysis treatment volumes held steady sequentially in the fourth quarter, while normalized growth in non-acquired treatments slipped compared to the previous year. Earnings could take a hit sooner than investors anticipate if patient volumes falter or the payor mix shifts.
The after-hours shift follows ongoing efforts to bounce back from operational hiccups and extra expenses linked to a prior cyberattack. Any unexpected jump in cybersecurity costs or staffing could dent the 2026 outlook.
Monday saw U.S. stocks climb, as the S&P 500 rose 0.54% and the Nasdaq nudged up 0.56%, setting a stronger tone ahead of a packed earnings schedule.
DaVita’s focus turns to management’s comments on reimbursement, labor, and treatment trends during the call. Investors will be watching closely to see if the after-hours rally sticks when the market opens Tuesday, February 3.
